Enhancement of PDGF-BB mitogenic activity on human dermal fibroblasts by biospecific dextran derivatives
Source abstract
Abstract
Dextran derivatives are biosynthetic polyanionic polymers which exert some of the heparin properties such as regulating the activity of several heparin-binding growth factors. Based on a reproducible synthetic procedure, we have synthesized a new generation of dextran derivatives named dextran methylcarboxylate benzylamide sulfate (DMCBSu). Here we investigated the ability of a library of well-characterized DMCBSu to interact with platelet-derived growth factor-BB (PDGF-BB), which has essential roles during wound healing. Using gel mobility shift assay, our results indicate that benzylamide and sulfate groups act synergically to bind to PDGF-BB. Furthermore we show that depending on their chemical composition, functionalized dextrans are able to potentiate the mitogenic activity of PDGF-BB on human dermal fibroblasts. This enhancing effect is accompanied with changes in PDGF-BB-induced signaling events, as determined by the use of specific inhibitors and by western blot. Our results suggest that the use of such biopolymers combined with a local administration of the growth factor could increase the efficiency of the biomolecule activity in future therapeutic strategies.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Proteoglycans and glycosaminoglycans research · Cell Adhesion Molecules Research · HER2/EGFR in Cancer Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Mechanism of action and in vivo role of platelet-derived growth factor10.1152/physrev.1999.79.4.1283 ↗
2. Roles of PDGF in animal development10.1242/dev.00721 ↗
3. Growth factors and chronic wound healing: past, present, and future10.1097/00129334-200401000-00012 ↗
4. Novel PDGF family members: PDGF-C and PDGF-D10.1016/S1359-6101(02)00090-4 ↗
5. Binding of platelet-derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human arterial smooth muscle cells10.1002/jcp.1041630218 ↗
6. Alternative splicing determines the binding of platelet-derived growth factor (PDGF-AA) to glycosaminoglycans10.1021/bi960118l ↗
7. Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans10.1007/s00418-003-0576-6 ↗
8. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain10.1074/jbc.272.9.5518 ↗
9. Processing of PDGF gene products determines interactions with glycosaminoglycans10.1002/(SICI)1099-1352(199903/04)12:2<112::AID-JMR452>3.0.CO;2-R ↗
10. Insights into the role of heparan sulphate in fibroblast growth factor signalling10.1042/BST0340442 ↗
11. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells10.1002/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B ↗
12. Heparin amplifies platelet-derived growth factor (PDGF)-BB-induced PDGF alpha-receptor but not PDGF beta -receptor tyrosine phosphorylation in heparan sulfate-deficient cells10.1074/jbc.M111805200 ↗
13. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: a review10.1002/(SICI)1097-4636(1999)48:4<578::AID-JBM26>3.0.CO;2-8 ↗
14. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF10.1002/jcp.1041500126 ↗
15. Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression10.1002/(SICI)1097-4636(199901)44:1<63::AID-JBM7>3.0.CO;2-S ↗
16. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta110.1016/S0945-053X(01)00131-7 ↗
17. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro10.1002/jbm.a.30723 ↗
18. Interaction of specifically chemically modified dextrans with transforming growth factor beta-1: potentiation of its biological activity10.1016/S0006-2952(01)00834-6 ↗
19. Effect of substituted dextran derivative on complement activation in vivo10.1016/0142-9612(95)93581-W ↗
20. Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran10.1016/S0008-6215(01)00066-0 ↗
21. Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer, efficient on muscle regeneration10.1002/jbm.10283 ↗
22. Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro10.1002/jbm.10192 ↗
23. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis10.1242/jcs.01607 ↗
24. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin10.1002/jbm.a.30874 ↗
25. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers10.1096/fj.02-0708com ↗
26. Periodontitis destructions are restored by synthetic glycosaminoglycan mimetic10.1002/jbm.a.30880 ↗
27. RGTA modulates the healing pattern of a defect in a monolayer of osteoblastic cells by acting on both proliferation and migration10.1002/jbm.a.10400 ↗
28. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-beta110.1096/fj.03-1126fje ↗
29. Human plasmin enzymatic activity is inhibited by chemically modified dextrans10.1074/jbc.M000837200 ↗
30. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G10.1016/S0014-5793(03)00064-4 ↗
31. Chaubet F, Huynh R, Dahri L, Correia J, Jozefowicz M, Jozefonvicz J. Dextran derivatives, preparation and medicinal applications. US Patent No. 6,646,120 B1.
32. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach10.1073/pnas.88.7.2768 ↗
33. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent
34. Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding10.1242/jcs.01322 ↗
35. Mechanism of human dermal fibroblast migration driven by type I collagen and platelet-derived growth factor-BB10.1091/mbc.e03-05-0352 ↗
36. Binding of heparin to basic fibroblast growth factor induces a conformational change10.1016/0003-9861(92)90401-H ↗
37. Effects of the binding of a dextran derivative on fibroblast growth factor 2: secondary structure and receptor-binding studies10.1016/S0006-2952(99)00051-9 ↗
38. Heparan sulfate upregulates platelet-derived growth factor receptors on human lung fibroblasts10.1093/glycob/8.12.1149 ↗
39. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor10.1083/jcb.111.4.1651 ↗
40. Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration10.1074/jbc.274.20.13954 ↗
41. Platelet-derived growth factor BB-induced p38 mitogen-activated protein kinase activation causes cell growth, but not apoptosis, in vascular smooth muscle cells10.1507/endocrj.48.433 ↗
42. p38 MAP kinase mediates platelet-derived growth factor-stimulated migration of hepatic myofibroblastes10.1002/jcp.10112 ↗
43. Changes in the balance of phosphoinositide 3-kinase/protein kinase B (Akt) and the mitogen-activated protein kinases (ERK/p38MAPK) determine a phenotype of visceral and vascular smooth muscle cells10.1083/jcb.145.4.727 ↗
44. Insulin inhibits PDGF-directed VSMC migration via NO/cGMP increase of MKP-1 and its inactivation of MAPKs10.1152/ajpcell.00110.2002 ↗
45. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering10.1016/j.addr.2007.03.016 ↗
46. Growth factor-delivery systems for tissue engineering: a materials perspective10.1586/17434440.3.1.29 ↗
47. Polysaccharide microarrays for polysaccharide-platelet-derived-growth-factor interaction studies10.1002/cbic.200500387 ↗